Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 14/20 | 1.00 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.69 |
| ▸ | DAO | P14920 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999370 | 0.85 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL16979047 | 0.84 | HCAR2 (0.72) | HCAR2HCAR3DAO | |
| SCHEMBL25678812 | 0.82 | HCAR2 (0.70) | HCAR2HCAR3DAO | |
| SCHEMBL1877148 | 0.82 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL5599447 | 0.82 | HCAR2 (0.75) | HCAR2HCAR3DAO | |
| SCHEMBL5599320 | 0.82 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL5599538 | 0.81 | HCAR2 (0.68) | HCAR2HCAR3DAO | |
| SCHEMBL5599509 | 0.81 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL5599633 | 0.80 | HCAR2 (0.67) | HCAR2HCAR3DAO | |
| SCHEMBL7172516 | 0.80 | HCAR2 (1.00) | HCAR2HCAR3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099648-A1 | PYRAOLO- AND TRIAZOLO-AZINONE COMPOUNDS AND THEIR USES | ASTRAZENECA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167094-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2021010492-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-21 | — | — | WO | disclosed |
| US-10835515-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | ORION CORPORATION (FI) | 2020-11-17 | — | — | US | disclosed |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190321333-A1 | CARBOXAMIDE DERIVATIVE AND ITS DIASTEREOMERS IN STABLE CRYSTALLINE FORM | ORION CORP (FI) | 2019-10-24 | — | — | US | disclosed |
| WO-2008140781-A1 | SPIRO COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | ATHEROGENICS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| CN-1893943-A | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-1696912-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005079195-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | HCAR2 3535/4885HCAR3 3093/4885DAO 1114/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | HCAR2 3979/4885HCAR3 3436/4885DAO 1381/4885 |
| US-20190321333-A1 | CARBOXAMIDE DERIVATIVE AND ITS DIASTEREOMERS IN STABLE CRYSTALLINE FORM | AR, NR5A1, SHBG | HCAR2 92/4885HCAR3 101/4885DAO 3950/4885 |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885HCAR3 3241/4885DAO 3336/4885 |
| US-10835515-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | AR, NR5A1, SHBG | HCAR2 92/4885HCAR3 101/4885DAO 3950/4885 |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | HCAR2 2298/4885HCAR3 2618/4885DAO 3475/4885 |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885HCAR3 3241/4885DAO 3336/4885 |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | NR3C2, PTGER2, PTGER1 | HCAR2 136/4885HCAR3 632/4885DAO 3501/4885 |
| US-20230167094-A1 | H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HRH2 | HCAR2 14/4885HCAR3 44/4885DAO 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.